VTViatris VTRS · NASDAQ
$18.66 +2.39% (+$0.44)
- Market cap
- $21.2B
- Enterprise value
- $34.0B
- P/E
- -
- Forward P/E
- 7.2x
- PEG
- -
- P/S
- 1.4x
- P/FCF
- 11.3x
- EV/EBITDA
- 12.9x
- ROIC
- -0.2%
- Bruto marža
- 34.8%
- Neto marža
- -2.8%
- Dividend yield
- 2.63%
- Payout ratio
- -
- Neto dolg/EBITDA
- 4.8x
- Beta
- 0.86
- Free float
- 99.4%
O podjetju
Viatris Inc. is a pharmaceutical company formed through the merger of two significant pharmaceutical firms. The company specializes in research, development, and manufacturing of prescription medicines, generic drugs, and biosimilars. Viatris offers a broad range of medications for various diseases, from common ailments to serious health conditions. The company is active in the global pharmaceutical market, providing treatment for millions of patients worldwide. Viatris focuses on improving accessibility and affordability of medicines and providing quality alternative treatment options. The company also invests in research for new drugs and treatment approaches to better address patients' healthcare needs. Viatris Inc. (VTRS) shares are an interesting choice for investors who follow the pharmaceutical sector and seek investment opportunities in a global pharmaceutical company with an extensive portfolio of medicines and research activities.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Scott Andrew Smith
Employees
30,000
Headquarters
Canonsburg
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke